Clinical Trial Search

Primary: Phase II Relapse of Body Dysmorphic Disorder (BDD) Symptoms (as Measured by the BDD-YBOCS) — 18; 40 percentage of subjects who relapsed — p=0.048

Primary: Co-primary: Body Weight- Mean Percent Change From Baseline to Week 28 — -6.45; -1.89 percentage of body weight — p=<0.001

Primary: Percentage of Successful Self-injections to Total Non-missed Injections — 97.8 percentage of successful injections

Primary: Co-primary: Body Weight- Mean Percent Change — -5.03; -1.75 percentage of body weight — p=<0.001

Primary: Progression Free Survival (PFS) as Assessed by Central Independent Review — 4.4; 3.6 months — p=0.0435

Primary: Safety - Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious AEs (SAEs) — 72; 7; 13 participants

Primary: Systolic and Diastolic Blood Pressure (SBP, DBP) — 127.2; 130.4; 75.9; 78.5 mm/Hg — p=<.05

Primary: Depression — 11; 18; 5; 11 participants — p=.067

Primary: Change in Hemoglobin A1C Level From Baseline — 0.09; -0.11 percentage of change from baseline — p=<0.05

Primary: Change From Baseline in Pruritus/Itch Score (Sum of Daytime and Nighttime Scores) Assessed by the Investigator at Week 2 — -1.63; -2.17 Score on a Scale — p=<0.001

Primary: Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks — -6.3; -6.1 units on a scale — p=0.883

Primary: Clinician-Administered PTSD Scale (CAPS) — 85.3; 88; 82.6 units on a scale

Primary: Change From Baseline in Intraocular Pressure (IOP) — -8.6; -9.0 mmHg

Primary: The Steady-state White Blood Cell Cystine Levels of RP103 Compared to Cystagon® — 0.5152; 0.4367 nmol ½ Cystine / mg protein — p=0.0001

Primary: Seroconversion Rate After Primary Vaccination — 100 percentage of seroconversion